Abstract:Abstract Introduction: Over expression and loss insensitivity to TGF-ß are two features which are coincident with CaP progression. In present study, we investigated whether a positive feedback pathway exists in which TGF-ß activates DNA methyltransferase (DNMT), which induces promoter hypermethylation. This hypermethylation may down-regulate TGF-ß receptors and in turn stimulate increased expression of TGF-ß. Materials and Methods: Human CaP cells (including the less aggressive lines, PC-3 and PC-3M-Pr04; and more aggressive lines, PC-3M and PC-3M-LN4) were rendered insensitive to TGF-ß using a retroviral vector containing a dominant negative TGF-ß type II receptor gene (TßRIIDN). ELISA were performed to quantify the secreted TGF-ß 1 (pg/105 cells/48 hours) in the pooled conditioned medium from CaP cells expressing T RIIDN and mock transfected. Semi-quantification western blot analyses were performed to evaluate the expression of DNA methyltransferase (DNMT), TßRI and TßRII. A [3H]-Thymidine Incorporation Assay was performed to determine cell proliferation rates in relation to TGF-ß. Results: Compared to PC-3 and PC-3M-Pr04, PC-3M and PC-3M-LN4 secreted almost 2 folds higher baseline levels of TGF-ß1 and DNMTs (1, 3α and 3ß). In contrast, TßRI and TßRII expression was significantly reduced in these same cell lines. In all cell lines, TßRIIDN expression was associated with significantly higher (∼1-2×) TGF-ß secretion, a greater than 3-fold decrease in the expression of DNMT1, DNMT3a, and DNMT 3b, and a correspondingly increased expression of both TßRI and TßRII (naïve intracellular domain). Although there was no significant difference in the original proliferation rate among PC3 variants, PC-3 and PC-3M-Pr04 cells were more sensitive to growth inhibition (>30%) by TGF-ß1 compared to PC-3M-LN4 and PC-3M cells (<7.5%). The growth inhibitory effects of TGF-ß1 disappeared when these cells were rendered insensitive to TGF-ß by infection with TßRIIDN. Conclusion: Higher expression of TGF-ß and lower expression of its own receptors are associated with more aggressive CaP phenotypes. Overexpression of tumor derived TGF-ß can activate DNMTs which will then mediate promoter methylation and down regulation of its receptors, subsequently, blockade of TGF-ß signaling may activate a feedback system which can stimulate the secretion of more TGF-ß. This novel mechanism has yet been reported, and may provide a new insight on TGF-ß regulation in prostate cancer. This study was supported in part by grants from the American Cancer Society, Illinois (#08-22), Department of Defense (W81XWH-09-1-0311), Portes Center/Institute of Medicine of Chicago (QZ), American Cancer Society Institutional Research Grant (ACS-IRG 93-037-12), American Urological Association Foundation (AUA Foundation, QZ), National Cancer Institute (P50CA090386), Illinois Department of Public Health (Contract #:83284034), a grant from the Genzyme Corporation, and a gift from Mr. Fred L. Turner. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr LB-85.

Manipulation of Prostate Cancer Metastasis by Locus-Specific Modification of the CRMP4 Promoter Region Using Chimeric TALE DNA Methyltransferase and Demethylase

Nonconserved Mir‐608 Suppresses Prostate Cancer Progression Through RAC2/PAK4/LIMK1 and BCL2L1/caspase‐3 Pathways by Targeting the 3′‐utrs of RAC2/BCL2L1 and the Coding Region of PAK4

Anti-androgen Therapy Induces Transcriptomic Reprogramming in Metastatic Castration-Resistant Prostate Cancer in a Murine Model.

Tgf-Beta Regulates Dna Methyltransferase Expression In Prostate Cancer, Correlates With Aggressive Capabilities, And Predicts Disease Recurrence

Expression profiling identifies new function of collapsin response mediator protein 4 as a metastasis-suppressor in prostate cancer

TGF-β regulates DNA methyltransferase expression in prostate cancer, correlates with aggressive capabilities, and predicts disease recurrence.

Prospective Study Of Crmp4 Promoter Methylation In Prostate Biopsies As A Predictor For Lymph Node Metastases

Upregulation of CRMP4, a New Prostate Cancer Metastasis Suppressor Gene, Inhibits Tumor Growth in a Nude Mouse Intratibial Injection Model.

Genome-Wide CRISPR-Cas9 Screening and Identification of Potential Genes Promoting Prostate Cancer Growth and Metastasis

CRISPR/Cas9 model of prostate cancer identifies Kmt2c deficiency as a metastatic driver by Odam/Cabs1 gene cluster expression

A Tmprss2-CreERT2 Knock-In Mouse Model for Cancer Genetic Studies on Prostate and Colon

An Atlas of Accessible Chromatin in Advanced Prostate Cancer Reveals the Epigenetic Evolution during Tumor Progression

Demethylation of EHMT1/GLP protein reprograms its transcriptional activity and promotes prostate cancer progression

The DNA methylation landscape of advanced prostate cancer

Differential Metastasis-Associated Gene Analysis of Prostate Carcinoma Cells Derived from Primary Tumor and Spontaneous Lymphatic Metastasis in Nude Mice with Orthotopic Implantation of Pc-3m Cells

Circulating Tumor DNA-targeted Sequencing to Reveal Germline and Somatic Alterations That Can Guide Decision-Making in Metastatic Castration-Resistant Prostate Cancer.

Supplementary Figure Legend from HIC1 Modulates Prostate Cancer Progression by Epigenetic Modification

A Study on Promoter Methylation of CRMP4 in Prostate Cancer

Involvement of aberrantly activated HOTAIR/EZH2/miR-193a feedback loop in progression of prostate cancer

Abstract LB-85: TGF-ß Regulates Its Own Expression and Down-Regulates Its Own Receptors in Prostate Cancer (cap) Cells Through a Positive Feedback Pathway Mediated by DNA Methyltransferase

Mp99-04 truncated-crmp4 by calpain-2 suppresses crmp4 to promote metastasis of prostate cancer via promoter methylation through e2f1/nf-?b/dnmt1 signaling